A cannabis product could be used as an antibiotic one day, Australian researchers say.
According to research presented at the American Society for Microbiology’s annual meeting, which takes place June 20-24 in San Francisco, the cannabis compound cannabidiol, more commonly known as CBD, holds potential for being used as an antibiotic one day.
Researchers found CBD “had a similar potency to established antibiotics such as vancomycin and daptomycin, and did not lose effectiveness after extended treatment.”
Dr. Mark Blaskovich, one of the researchers from the Institute for Molecular Bioscience at the University of Queensland, told the Daily News that studies showed CBD worked “in vivo” or in animal models, as a topical treatment or possibly on bacteria on the skin before surgery.
Unlike some bacteria that have become increasingly resistant to antibiotics, the researchers found that CBD did not lose effectiveness over time.
During the research, CBD was effective against every Gram-positive bacteria that was tested. CBD was selective for Gram-positive and not Gram-negative however, meaning the CBD would not be effective against the Gram-negative bacteria.
Gram-negative bacteria have a thin cell membrane, but it can be difficult to penetrate. This means they can be more difficult to treat with antibiotics, according to the American College of Healthcare Sciences.
“It is not effective against Gram-negative bacteria, which are especially difficult to develop new antibiotics for because they have a very selective outer-membrane that prevents most drugs from entering the bacterial cell,” Edwards told Newsweek.
In addition to its potential use as an antibiotic, Blaskovich said CBD could come with other benefits.
Blaskovich said further research is required to show if it could be used against internal infections, but that it could appear in a pill form of some kind if that was proven through studies.
Despite the promising studies, Blaskovich advised people to keep using approved medication until further research is done.
Blaskovich said because CBD has gained approval as a drug in medication such as Epidiolex, which is used to treat seizures, the regulatory pathway to gain approval “should be much shorter than normal for a new antibiotic.”
Botanix, the company that funded the study, is aiming to begin a Phase 1 or 2 trial by the end of this year, Blaskovich said.
Read more: nydailynews.com